Deals
A decade after Teva was slapped with a ten-figure fine for its alleged illegal activities blocking US generic competition to its Provigil brand, the Israeli firm has offloaded the narcolepsy drug and follow-up brand Nuvigil in the US to Apotex.
Teva has announced two major biosimilars deals in quick succession, partnering with Samsung Bioepis on its US Epysqli eculizumab rival to Soliris and Formycon on its European Ahzantive aflibercept challenger to Eylea.
Neuraxpharm’s business development team remains busy entering the new year, after signing yet another strategic deal – this time to grow the firm’s core presence in CNS disorder drugs.
Fresenius Kabi is to diversify its offering beyond immunology and oncology after putting pen to paper on a deal for a US biosimilar to Eylea, in the wake of Amgen’s surprise at-risk launch.
2024 was truly a dealmaking year for Bio-Thera, with the latest partnership expanding the net for its ustekinumab biosimilar.
Chinese biosimilars developer Bio-Thera is expanding its Latin American partnership with SteinCares with the addition of a third product.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
Synthon’s current owners, BC Partners, are selling a controlling stake in the Dutch complex generics specialist to Goldman Sachs Asset Management.
The two companies have signed a co-development agreement focused on the potential creation of new long-acting injectable therapies for psychiatric conditions for an undisclosed financial sum.
Amid rumors that Stada is sounding out investors for an IPO valued at around €1.5bn – following suggestions earlier this year that the company was being shopped around to potential buyers – the German generics giant has acknowledged to Generics Bulletin that options under review could include a sale or IPO.
Hikma has marked a major step forward in US biosimilars by filing with the US Food and Drug Administration its Gedeon Richter-partnered denosumab rival to Prolia and Xgeva.
Rosemont Pharmaceuticals will commercialize Hyloris’ proprietary valacyclovir oral suspension in the US under a new partnership that has been agreed between the two firms.
Formycon and MS Pharma have followed up on previous biosimilar collaborations in the MENA region with a fresh alliance on Stelara rival FYB202.
Indian player Indoco has struck a deal with UK distributor Clarity Pharma that will allow it to target the UK market with the launch of 20 products over the next 18 months.
Coherus is fully exiting the biosimilars space after striking a final deal worth up to $558m to divest its Udenyca US pegfilgrastim franchise to Accord parent company Intas.
Viatris is shedding another of its off-patent interests, striking a deal for Safecor Health to acquire its US unit-dose packaging business.
Zentiva is moving ahead with its takeover of Apontis Pharma after its voluntary public purchase offer resulted in it securing almost 84% of share capital and a more than 85% share of voting rights.
Aurobindo has revealed details of a product development and commercialization deal that it has struck for multiple respiratory products. However, the identity of its “global pharma major” partner remains a mystery for now.
MSN Laboratories has struck a patent-litigation settlement deal with BeiGene that will allow it to launch its zanubrutinib generic rival to Brukinsa in the US from 2037.
Having previously set itself a deadline of the end of November to strike a licensing deal for one of two biosimilar candidates – or risk failing to meet its working capital requirements – Sweden’s Xbrane has now announced a global licensing partnership with Intas for its nivolumab Opdivo rival, with just days to spare.